Kollberg H - Search Results

1

Increased serum concentrations of carbohydrate-deficient transferrin (CDT) in patients with cystic fibrosis.

Larsson A, Flodin M, Kollberg H. Larsson A, et al. Among authors: kollberg h. Ups J Med Sci. 1998;103(3):231-6. doi: 10.3109/03009739809178952. Ups J Med Sci. 1998. PMID: 10052112

2

Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study.

Kollberg H, Carlander D, Olesen H, Wejåker PE, Johannesson M, Larsson A. Kollberg H, et al. Pediatr Pulmonol. 2003 Jun;35(6):433-40. doi: 10.1002/ppul.10290. Pediatr Pulmonol. 2003. PMID: 12746939 Clinical Trial.

3

Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients.

Nilsson E, Larsson A, Olesen HV, Wejåker PE, Kollberg H. Nilsson E, et al. Among authors: kollberg h. Pediatr Pulmonol. 2008 Sep;43(9):892-9. doi: 10.1002/ppul.20875. Pediatr Pulmonol. 2008. PMID: 18680179

4

More than 10 years' continuous oral treatment with specific immunoglobulin Y for the prevention of Pseudomonas aeruginosa infections: a case report.

Nilsson E, Kollberg H, Johannesson M, Wejåker PE, Carlander D, Larsson A. Nilsson E, et al. Among authors: kollberg h. J Med Food. 2007 Jun;10(2):375-8. doi: 10.1089/jmf.2006.214. J Med Food. 2007. PMID: 17651078

5

Immunoreactive trypsin screening for cystic fibrosis.

Borgström A, Sveger T, Lindberg T, Kollberg H, Larsson A. Borgström A, et al. Among authors: kollberg h. Acta Paediatr Scand. 1982 Jul;71(4):621-4. doi: 10.1111/j.1651-2227.1982.tb09485.x. Acta Paediatr Scand. 1982. PMID: 7136678

6

Peroral immunotherapy with yolk antibodies for the prevention and treatment of enteric infections.

Carlander D, Kollberg H, Wejåker PE, Larsson A. Carlander D, et al. Among authors: kollberg h. Immunol Res. 2000;21(1):1-6. doi: 10.1385/ir:21:1:1. Immunol Res. 2000. PMID: 10803878 Free PMC article. Review.

7

Retention of specific yolk IgY in the human oral cavity.

Carlander D, Kollberg H, Larsson A. Carlander D, et al. Among authors: kollberg h. BioDrugs. 2002;16(6):433-7. doi: 10.2165/00063030-200216060-00004. BioDrugs. 2002. PMID: 12463766 Clinical Trial.

8

Fatty acids in cystic fibrosis in response to a marathon race.

Ceder O, Bardón A, Kollberg H, Stanghelle JK, Maehlum S, Skyberg D, Custance J, Dodge J. Ceder O, et al. Among authors: kollberg h. Int J Sports Med. 1988 Feb;9 Suppl 1:51-5. doi: 10.1055/s-2008-1025615. Int J Sports Med. 1988. PMID: 3360545

9

Cystic fibrosis and physical activity: an introduction.

Kollberg H. Kollberg H. Int J Sports Med. 1988 Feb;9 Suppl 1:2-5. doi: 10.1055/s-2007-1025055. Int J Sports Med. 1988. PMID: 3360539

10

Dopamine and catecholamines in cystic fibrosis in response to a marathon race.

Kollberg H, Schöni M, Türler K, Käser H, Bardón A, Ceder O, Stanghelle JK, Maehlum S, Skyberg D. Kollberg H, et al. Int J Sports Med. 1988 Feb;9 Suppl 1:56-9. doi: 10.1055/s-2008-1025616. Int J Sports Med. 1988. PMID: 3360546

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

81 results

Search Page

Filters